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databases from 1990–June 2007 were systematically searched for
RCTs evaluating the efﬁcacy of PPIs on nighttime symptoms in
adults with GERD. Methodological and clinical homogeneity
across studies was explored. Methodological diversity or differ-
ences in study quality evaluated by Jadad score (ranging from
1 = low to 5 = high) and clinical diversity in nighttime criteria
used for patient enrollment, nighttime outcomes measured, and
the nighttime deﬁnition used were explored. RESULTS: Thirty-
two RCTs compared the efﬁcacy of PPI with placebo only (n = 7),
H2-receptor antagonist only (n = 12), another PPI only (n = 11)
or both placebo and H2-receptor antagonist (n = 2) in control-
ling nighttime GERD. The majority of studies (n = 28) were of
high methodological quality (Jadad score of at least 3 points).
Source of data collection was patient daily diaries across all
studies. Criteria for enrolling nighttime GERD patients (fre-
quency and/or severity of nighttime symptoms) lacked consis-
tency. Nighttime heartburn measures varied from percentage of
patients without heartburn (n = 18), percentage of heartburn-
free nights (n = 15), heartburn severity score (n = 11) or time to
heartburn relief (n = 6). Most studies assessed efﬁcacy at eight
weeks or less; only three studies measured the long-term efﬁcacy
of PPI. However, very few nighttime heartburn measures assessed
the same timeframe. The time window for the nighttime
symptom assessment was reported in only three studies and was
not based on speciﬁc hours but on sleep/posture (retiring/lying
down to sleep). CONCLUSION: RCTs of PPI therapy in night-
time GERD are of high methodological quality. However,
presence of clinical heterogeneity across trials in enrollment cri-
teria, outcomes, and timeframes minimizes the possibility of
performing meta-analysis.
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OBJECTIVE: To compare the rate of hospitalizations for serious
upper and lower GI events in patients with increased GI risk
taking a Traditional NSAID (tNSAID)+Proton Pump Inhibitor
(PPI) or a COX-2 selective inhibitor (Coxib), chronic and acute.
METHODS: From the PHARMO Record Linkage System,
including among others linked drug-dispensing and hospital
records of approximately three million individuals in The Neth-
erlands, we selected new users of Coxibs or tNSAIDs between
January 1, 2000 and December 31, 2004. Eligible patients had
1 year history before the 1st NSAID dispensing and 1 year
follow-up which ended at ﬁrst hospitalization for serious GI
event (the outcome), the last dispensing, or the end of the study
period. Chronic users were deﬁned as patients who used any
NSAIDs for 60 days during the ﬁrst year of follow-up
(n = 58770); other NSAID users were acute users (n = 538.420).
Multivariate analysis by Poisson regression adjusted for sex, age,
duration of follow-up, tNSAID and coxib dose, adherence to
NSAIDs or PPIs, gastroprotection, anticoagulants, acetami-
nophen, corticosteroids, and cardiovascular disease. RESULTS:
The cohort included 52,953 new tNSAIDs+PPI users and 80,756
new Coxib users, with main characteristics: mean (SD) age
58.1  15.5 vs. 56.7  17.5; female 55.3% vs. 62.2%; mean
duration of treatment (days): 137  217 vs. 138  179, respec-
tively. Among acute users, adjusted hazard ratios (95% Conﬁ-
dence Interval) of hospitalizations were 0.21 (0.14–0.32) for
upper and 0.26 (0.16–0.42) for lower GI events, for Coxib versus
tNSAIDs+PPI users. Among chronic users, adjusted hazard ratios
were 0.35 (0.22–0.55) for upper GI and 0.43 (0.25–0.75) for
lower GI events, for Coxib versus tNSAIDs+PPI users. CON-
CLUSION: Acute and chronic Coxib users had a statistically
signiﬁcantly lower rate of hospitalizations for upper and lower
GI events compared to tNSAIDS+PPI users. Future research is
needed to explain these ﬁndings, possibly due to prescribing for
non-preventive reasons.
GASTROINTESTINAL DISORDERS—Cost Studies
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OBJECTIVE: Ulcerative colitis (UC) is a chronic condition that
afﬂicts young adults in their economically productive years.
Because of its long duration, UC causes high use of health ser-
vices and high lifetime costs for medical care. The aim of this
study was to measure the annual costs of patients with UC from
the Brazilian public heath perspective and to identify potentially
relevant determinants of costs. METHODS: Thirty-one gastro-
enterologists from southeast Brazil prospectively evaluated all
their UC patients during two months. They used a structured
questionnaire speciﬁcally developed to evaluate resource use by
patients with ulcerative colitis. Costs of medical services (diag-
nostics and treatment) were considered as well as costs of
medication. Resource use was valued using government reim-
bursement for hospital services and government tender prices
drugs. RESULTS: A total of 175 patients were evaluated. The
mean annual cost of one CD patient was R$1945.06, including
medication, physician, laboratory, diagnostic, hospitalization
and surgery costs. Medication, hospitalization, surgery and diag-
nostic procedures accounted respectively for 95%, 3%, 1%, and
1% of the total annual costs. Mesalazine was the most used drug
to initiate UC′s treatment (58%). There was no statistical differ-
ence between the costs of the patients treated with mesalazine
and sulfasalazine. Due to differences in the mean dosage of theses
drugs, mesalazine daily cost is lower than sulfasalazine. CON-
CLUSION: This is the ﬁrst time that UC treatment costs have
been demonstrated from the Brazilian public health perspective.
Although mesalazine is deemed to be more expensive than sul-
fasalazine and considering that there was no statistical difference
in total costs among patients taking mesalazine and sulfasalazine,
and that medications represent more than 90% of total UC
treatment annual costs in the public Brazilian health care system,
the use of mesalazine may represent a reduction factor in the
ﬁnancial resource expenditure for the treatment of UC.
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OBJECTIVE: Inﬂiximab improves patient quality of life and is
effective to control Crohn’s disease refractory to the standard
treatment. It lacks real world Brazilian data demonstrating that
this improvement in quality of life and disease control is related
to decrease of resource use mainly due to hospitalization reduc-
tion in moderate and severe Crohn disease patients receiving
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inﬂiximab. METHODS: Thirty one gastroenterologists from
southeast Brazil prospectively evaluated all their Crohn’s disease
patients during two months. They used a structured question-
naire speciﬁcally developed to evaluate resource use by patients
with Crohn’s disease. RESULTS: A total of 118 patients with
moderate and severe disease were evaluated during 2 months.
The patients average age was 30 years and the mean body weight
was 62 kg. Fourteen patients were using inﬂiximab. The com-
parison among inﬂiximab patients and standard care patients
showed that 60.6% of the standard care patients needed hospi-
talization and only 21.4% of the inﬂiximab patients needed
hospitalization (p = 0.005). The main reason for hospitalization
among the standard care patients was due to anal ﬁstula, and
among the inﬂiximab patients, was due to anemia/hemorrhage.
CONCLUSION: The use of inﬂiximab in the management of
moderate and severe Crohn’s disease can be contributive to
reduction of the need of hospitalization among these patients.
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OBJECTIVE: To compare the cost-effectiveness (CE) of natali-
zumab (NAT) to FDA-approved tumor-necrosis factor alpha
inhibitors (anti-TNFa) in Crohn’s disease (CD). METHODS:
Decision analysis was used to model treatment for patients with
moderate-to-severe CD (Crohn’s Disease Activity Index scores
220 and <450). Patients are assumed to have failed treat-
ment with corticosteroids, immunomodulators, and anti-TNFa
therapy. The model includes an induction phase followed by a
two year maintenance phase comparing NAT 300 mg, inﬂiximab
(INF) 5 mg/kg or 10 mg/kg, and adalimumab (ADA) 40 mg
every other week or weekly. At the end of induction and each of
the four six-month maintenance cycles, patients enter one of
three efﬁcacy states (remission, response, nonresponse) that are
estimated from phase III clinical studies and NAT clinical data.
Total costs associated with each comparator agent are composed
of pharmacy and medical costs derived from published price lists
and analyses of CD claims from a database assembled by Health
Benchmarks International. Drug costs for INF and ADA were
weighted by dose based upon the distribution observed in pub-
lished phase IV studies. RESULTS: Over the two year mainte-
nance period, NAT patients on average were estimated to be in
remission for 0.41 years versus 0.22 and 0.26 for those receiving
INF and ADA, respectively. Average total costs over induction
and maintenance were predicted to be $62,377 (NAT), $55,195
(INF), and $56,654 (ADA). NAT was associated with 13% and
10% increases in total cost compared to INF and ADA, but
resulted in 86% and 57% increases in remission duration over
the comparators, respectively. The CE ratio for NAT relative to
ADA and INF remained insensitive to increases in NAT-related
costs (up to $36,000) or decreases in NAT efﬁcacy (up to -25%).
CONCLUSION: This model, based on estimates from the avail-
able published literature, projected NAT to be the most cost-
effective treatment alternative for patients who had failed prior
anti-TNFa therapy.
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OBJECTIVE: Recombinant factor VIIa, an expensive coagula-
tion factor, was previously utilized pre-operatively at UC San
Diego Medical Center (UCSDMC) to reduce blood loss during
Orthotopic Liver Transplant (OLT). Recent large randomized,
controlled clinical trials have demonstrated a lack of efﬁcacy and
a potential risk of thromboembolic complications. As a result,
use of recombinant factor VIIa for bleeding prophylaxis in OLT
was discouraged due to compromised cost-effectiveness. This
change in practice warranted validation through pharmacoeco-
nomic outcomes research. METHODS: A single-center, retro-
spective review was performed to determine if the change in
UCSDMC OLT guidelines resulted in negative outcomes. The
primary outcome measure was the volume of blood products
required during OLT. Secondary outcomes included total cost of
care, operating room time, LOS, and thromboembolic events.
RESULTS: 119 liver transplant recipients were included in the
analysis. There was no signiﬁcant difference in the primary
outcome of blood product requirement. Patients receiving factor
VIIa failed to demonstrate any statistically signiﬁcant reduction
in need for PRBC 13.8 vs 13.4 units (p = 0.9), FFP 11.3 vs 15.6
(p = 0.2), or PLT 4 vs 6.6 (p = 0.08) when compared to controls.
The secondary outcome measurements also failed to reach sta-
tistical signiﬁcance, including LOS 23 vs 15 days (p = 0.17),
blood costs (p = 0.92), surgical costs (p = 0.69), and total cost of
care (p = 0.15). Two patients developed hepatic artery thrombo-
sis in the treatment group compared to one patient in the control
group. As measured by the Scientiﬁc Registry of Transplant
Recipients (SRTR), no signiﬁcant changes in liver transplant
patient or graft survival were noted. An 83% reduction average
recombinant factor VIIa use during OLT has been demonstrated,
resulting in annual savings of $170 K. CONCLUSION: Recom-
binant factor VIIa use for reduction of blood product require-
ments in OLT has not been demonstrated to be cost-effective and
may be associated with a risk of thromboembolic events.
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OBJECTIVE: Associated with no screening, H. pylori serology
screening, and the 13C-Urea breath test (UBT) for gastric cancer
in Chinese. METHODS: A Markov model simulation was
carried out in Singaporean Chinese at age of 40 years
(n = 478,500) from the perspective of public health care provid-
ers. The main outcome measures were costs, number of gastric
cancer cases prevented, life years saved, quality-adjusted life-
years (QALYs) gained from the screening age to death, and
incremental cost-effectiveness ratios (ICERs), which were com-
pared among the three strategies. The uncertainty surrounding
ICERs was addressed by scenario analyses and probabilistic sen-
sitivity analysis using Monte Carlo simulation. RESULTS: The
ICER of serology screening versus no screening was $25,881 per
QALY gained (95% conﬁdence interval (95% CI): $5700 to
$120,000). The ICER of UBT versus no screening was $53,602
per QALY gained (95% CI: $16,000 to $230,000). ICER of UBT
versus serology screening was $470,000 per QALY gained, for
which almost all random samples of the ICERs distributed above
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